Difference between subjective and objective cognitive decline confirmed by power spectral density.

Area of Science:

• Neuroscience
• Biomarkers
• Alzheimer's Disease Research

Background:

• Subjective cognitive decline (SCD) and amnestic mild cognitive impairment (aMCI) represent preclinical stages of Alzheimer's disease (AD).
• Early diagnosis of AD is crucial for timely intervention and management.
• Identifying reliable biomarkers for preclinical AD is an ongoing research priority.

Purpose of the Study:

• To investigate power spectrum changes in electroencephalography (EEG) as potential biomarkers for SCD and aMCI.
• To explore the utility of relative power spectral density (PSD) in differentiating between SCD and aMCI.
• To assess the potential of EEG-based biomarkers for early Alzheimer's disease diagnosis.

Main Methods:

• Recruited 23 SCD and 32 aMCI subjects for comparative analysis.
• Utilized relative power spectral density (PSD) analysis of resting-state EEG data.
• Employed automated preprocessing and statistical analysis via iSync Brain® software.

Main Results:

• Significant differences in theta band power were observed in temporal and parietal regions between SCD and aMCI groups.
• Beta1 band power showed distinct patterns in the frontal and temporal regions differentiating the two groups.
• PSD analysis revealed electrical-physiological characteristics distinguishing preclinical AD stages.

Conclusions:

• Resting-state EEG PSD analysis shows promise in predicting subjective cognitive decline (SCD), an early stage of Alzheimer's disease (AD).
• This study highlights the potential of EEG-based measures as biomarkers for preclinical AD.
• Further longitudinal studies are required to confirm the predictive value of these findings for future cognitive decline.